| Reference | 1: Hang Y, Chen Y, Xue L, Sun S, Liu L, Gao J, Xie C, Zhang X, Zhu J, Jin J, Miao L. Evaluating biapenem dosage regimens in intensive care unit patients with Pseudomonas aeruginosa infections: A pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation. Int J Antimicrob Agents. 2017 Jul 11. pii: S0924-8579(17)30279-0. doi: 10.1016/j.ijantimicag.2017.07.005. [Epub ahead of print] PubMed PMID: 28709989.<br />
2: Kaushik A, Ammerman NC, Tasneen R, Story-Roller E, Dooley KE, Dorman SE, Nuermberger EL, Lamichhane G. In vitro and in vivo activity of biapenem against drug-susceptible and rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 2017 Aug 1;72(8):2320-2325. doi: 10.1093/jac/dkx152. PubMed PMID: 28575382.<br />
3: Bianchet MA, Pan YH, Basta LAB, Saavedra H, Lloyd EP, Kumar P, Mattoo R, Townsend CA, Lamichhane G. Structural insight into the inactivation of Mycobacterium tuberculosis non-classical transpeptidase Ldt(Mt2) by biapenem and tebipenem. BMC Biochem. 2017 May 25;18(1):8. doi: 10.1186/s12858-017-0082-4. PubMed PMID: 28545389; PubMed Central PMCID: PMC5445500.<br />
4: Dong J, Xiong W, Chen Y, Zhao Y, Lu Y, Zhao D, Li W, Liu Y, Chen X. Optimal dosing regimen of biapenem in Chinese patients with lower respiratory tract infections based on population pharmacokinetic/pharmacodynamic modelling and Monte Carlo simulation. Int J Antimicrob Agents. 2016 Mar;47(3):202-9. doi: 10.1016/j.ijantimicag.2015.12.018. Epub 2016 Jan 30. PubMed PMID: 26895604.<br />
5: Akashita G, Hosaka Y, Noda T, Isoda K, Shimada T, Sawamoto K, Miyamoto K, Taniguchi T, Sai Y. PK/PD analysis of biapenem in patients undergoing continuous hemodiafiltration. J Pharm Health Care Sci. 2015 Nov 14;1:31. doi: 10.1186/s40780-015-0031-6. eCollection 2015. PubMed PMID: 26819742; PubMed Central PMCID: PMC4728804.<br />
6: Dong J, Chen YC, Xiong W, Zhao YF, Sun YB, Lu Y, Liu YH, Li WY, Chen XJ. Efficacy and safety of biapenem against lower respiratory tract infections in elderly Chinese patients and optimal dosing regimen based on pharmacokinetic/pharmacodynamic analysis. J Chemother. 2016 Oct;28(5):403-10. doi: 10.1179/1973947815Y.0000000078. PubMed PMID: 26430768.<br />
7: Okimoto N, Kawai Y, Katoh T, Hayashi T, Kurihara T, Miyashita N. Clinical effect of biapenem on nursing and healthcare-associated pneumonia (NHCAP). J Infect Chemother. 2015 Aug;21(8):592-5. doi: 10.1016/j.jiac.2015.05.001. Epub 2015 May 16. PubMed PMID: 26050019.<br />
8: Pei G, Yin W, Zhang Y, Wang T, Mao Y, Sun Y. Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials. J Chemother. 2016;28(1):28-36. doi: 10.1179/1973947814Y.0000000226. PubMed PMID: 25407221.<br />
9: Rajenderan S, Balaji V, Anandan S, Sahni RD, Tansarli GS, Falagas ME. Determination of MIC distribution of arbekacin, cefminox, fosfomycin, biapenem and other antibiotics against gram-negative clinical isolates in South India: a prospective study. PLoS One. 2014 Jul 28;9(7):e103253. doi: 10.1371/journal.pone.0103253. eCollection 2014. PubMed PMID: 25068396; PubMed Central PMCID: PMC4113358.<br />
10: Namkoong H, Kameyama Y, Yasuda H, Nakayama S, Kaneko H, Kawashima C, Terajima T, Maezawa K, Hayashi T, Sandoh M, Ishii M, Tasaka S, Kanayama A, Kobayashi I, Betsuyaku T, Kizu J, Iwata S, Sato Y, Hasegawa N. The efficacy, safety, and pharmacokinetics of biapenem administered thrice daily for the treatment of pneumonia in the elderly. J Infect Chemother. 2014 Jun;20(6):356-60. doi: 10.1016/j.jiac.2013.12.010. Epub 2014 Apr 13. PubMed PMID: 24725621.
|
